SAM
AVIR icon

Smartleaf Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Smartleaf Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.9K Buy
3,325
+25
+0.8% +$115 ﹤0.01% 2047
2025
Q4 		$11.7K Buy
+3,300
New +$10.5K ﹤0.01% 2323
2024
Q3 		– Sell
-46
Closed -$155 – 2910
2024
Q2 		$155 Buy
+46
New +$172 ﹤0.01% 2701

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Smartleaf Asset Management's AVIR Position: Q1 2026 in Review

Smartleaf Asset Management increased its Atea Pharmaceuticals (AVIR) stake by 0.76% in Q1 2026, buying an estimated $115 and bringing the position to 3,325 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2047.

Smartleaf Asset Management first reported a position in AVIR in Q2 2024 and has held it in 3 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Smartleaf Asset Management held 3,325 shares of Atea Pharmaceuticals worth $16.9K as of Q1 2026.
  • Smartleaf Asset Management bought 25 Atea Pharmaceuticals shares in Q1 2026, an estimated $115.
  • Atea Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2047 holding.
  • Smartleaf Asset Management first reported a position in Atea Pharmaceuticals in Q2 2024 and has held it in 3 quarters since.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.